在癌症中与酶融合,突变和副本数量改变的可操作变化的比较
Shinsuke Suzuki1,2,3, Toshiaki Akahane1,4, Akihide Tanimoto4
1Cancer Center, Kagoshima University Hospital, Kagoshima, Japan.
PloS one
|January 23, 2025
概括
激酶融合是癌症的关键驱动因素,但这些变化的患者的可操作目标比突变或副本数量变化的患者少. 检测激酶变化对于开发向疗法至关重要.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 分子生物学分子生物学
背景情况:
- 激酶基因融合和突变是癌症的关键驱动因素,需要向治疗.
- 虽然向疗法在酶融合方面表现出成功,但它们在固体瘤中的作用不太清楚.
- 可操作的变化,包括酶融合,对于个性化癌症治疗至关重要.
研究的目的:
- 为了比较具有酶融合,突变和拷贝数改变 (CNAs) 的患者的可操作变化的数量.
- 评估各种固体瘤类型中可操作的基因组变化的频率和分布.
主要方法:
- 在613名固体瘤患者中使用FoundationOne® (F1CDx) 和FoundationOne®液体 (F1LCDx) 进行了全面的基因组分析.
- 分析患者特征和基因组资料,以确定酶融合,突变和CNA.
- 根据检测到的激酶变化的类型,对可操作变化的数量进行比较.
主要成果:
- 在44名患有各种融合的患者中检测到13个酶-域融合.
- 117名患者患有酶域突变,58人患有酶域CNA.
- 与突变 (中位数5) 和CNA (中位数6) 相比,基因酶融合患者的可操作性改变较少 (中位数2).
- 涉及瘤抑制剂的融合与更容易采取行动的变化有关 (中位数4).
结论:
- 具有酶融合的癌症比具有酶突变或CNAs的癌症显示出更少的可操作变化.
- 激酶融合是癌症的重要驱动因素,是分子治疗的有希望的目标.
- 全面的基因组分析对于识别激酶变异和指导向治疗策略至关重要.
相关概念视频
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Cancer-Critical Genes I: Proto-oncogenes
8.7K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.7K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Cancers Originate from Somatic Mutations in a Single Cell
11.5K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
11.5K
Comparing Copy Number Variations and SNPs
17.1K
Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
17.1K


